Related Experiment Video
Updated: Aug 2, 2026
09:07
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
Association study of mast cell chymase polymorphisms with atopy
S Weidinger1, L Rümmler, N Klopp
1Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.
Allergy
|September 2, 2005
Summary
Genetic variations in the mast cell chymase gene (CMA1) are linked to atopic eczema. Specifically, the rs1800875 promoter polymorphism is significantly associated with this condition, supporting CMA1 as a candidate gene.
Area of Science:
- Immunogenetics
- Dermatology
- Molecular Biology
Background:
- Atopic disorders arise from complex genetic and environmental interactions.
- Previous studies on the mast cell chymase gene (CMA1) promoter polymorphism rs1800875 and atopy phenotypes yielded inconsistent results.
Purpose of the Study:
- To investigate the association between CMA1 gene polymorphisms and atopic phenotypes.
- To clarify the role of CMA1 in the pathogenesis of atopic eczema.
Main Methods:
- Sequencing of the CMA1 locus in healthy and atopic eczema individuals.
- Evaluation of seven CMA1 single nucleotide polymorphisms (SNPs) in a large German adult population (n=1875).
- Phenotyping through questionnaires, interviews, skin prick testing, and serum IgE measurements; genotyping via MALDI-TOF MS.
Main Results:
- The promoter polymorphism rs1800875 showed a significant association with atopic eczema.
- No significant associations were found for other individual SNPs.
- Haplotype analysis revealed two haplotypes with borderline significance for atopic eczema, which did not persist after multiple testing correction.
Conclusions:
- The study confirms a significant association between the CMA1 promoter polymorphism rs1800875 and atopic eczema.
- This finding supports the hypothesis that CMA1 is a candidate gene for atopic eczema.
- No association was detected between CMA1 polymorphisms and serum IgE levels.
Related Concept Videos
02:06Allergic Reactions
Overview
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...